Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01661335 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Aprepitant (Emend®) in Children
A Phase 3 study, sponsored by University of Oklahoma.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
NCT01661335 is a Phase 3 study that has completed, run by University of Oklahoma. The registered enrollment target is 19 participants.
The verdict
NCT01661335, a Phase 3 study, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
Interventions
- DRUG Ondansetron, dexamethasone, aprepitant
- DRUG Ondansetron, Dexamethasone, placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-06-01 |
| Est. Completion | 2017-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01661335
The ClinicalTrials.gov registry entry for NCT01661335 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ondansetron, dexamethasone, aprepitant is the first listed.
NCT01661335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01661335 about?
NCT01661335 is a clinical study titled "Efficacy of Aprepitant (Emend®) in Children". The purpose of this study is to find out whether or not adding aprepitant(Emend®) to the standard therapy will help children who receive chemotherapy to have less nausea and vomiting.
What is the current status of trial NCT01661335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2012-06-01. Estimated completion is 2017-06-29.
What interventions are being tested in trial NCT01661335?
The interventions under investigation include: Ondansetron, dexamethasone, aprepitant (DRUG), Ondansetron, Dexamethasone, placebo (DRUG).
Who is sponsoring clinical trial NCT01661335?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.